FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024001803> ?p ?o ?g. }

• W2024001803 endingPage "4818" @default.
• W2024001803 startingPage "4800" @default.
• W2024001803 abstract "All of the selective COX-2 inhibitors described to date inhibit the isoform by binding tightly but noncovalently at the substrate binding site. Recently, we reported the first account of selective covalent modification of COX-2 by a novel inactivator, 2-acetoxyphenyl hept-2-ynyl sulfide (70) (Science 1998, 280, 1268−1270). Compound 70 selectively inactivates COX-2 by acetylating the same serine residue that aspirin acetylates. This paper describes the extensive structure−activity relationship (SAR) studies on the initial lead compound 2-acetoxyphenyl methyl sulfide (36) that led to the discovery of 70. Extension of the S-alkyl chain in 36 with higher alkyl homologues led to significant increases in inhibitory potency. The heptyl chain in 2-acetoxyphenyl heptyl sulfide (46) was optimum for COX-2 inhibitory potency, and introduction of a triple bond in the heptyl chain (compound 70) led to further increments in potency and selectivity. The alkynyl analogues were more potent and selective COX-2 inhibitors than the corresponding alkyl homologues. Sulfides were more potent and selective COX-2 inhibitors than the corresponding sulfoxides or sulfones or other heteroatom-containing compounds. In addition to inhibiting purified COX-2, 36, 46, and 70 also inhibited COX-2 activity in murine macrophages. Analogue 36 which displayed moderate potency and selectivity against purified human COX-2 was a potent inhibitor of COX-2 activity in the mouse macrophages. Tryptic digestion and peptide mapping of COX-2 reacted with [1-14C-acetyl]-36 indicated that selective COX-2 inhibition by 36 also resulted in the acetylation of Ser516. That COX-2 inhibition by aspirin resulted from the acetylation of Ser516 was confirmed by tryptic digestion and peptide mapping of COX-2 labeled with [1-14C-acetyl]salicyclic acid. The efficacy of the sulfides in inhibiting COX-2 activity in inflammatory cells, our recent results on the selectivity of 70 in attenuating growth of COX-2-expressing colon cancer cells, and its selectivity for inhibition of COX-2 over COX-1 in vivo indicate that this novel class of covalent modifiers may serve as potential therapeutic agents in inflammatory and proliferative disorders." @default.
• W2024001803 created "2016-06-24" @default.
• W2024001803 creator A5010503382 @default.
• W2024001803 creator A5017995984 @default.
• W2024001803 creator A5035452503 @default.
• W2024001803 creator A5039874956 @default.
• W2024001803 creator A5057630285 @default.
• W2024001803 date "1998-10-17" @default.
• W2024001803 modified "2023-10-03" @default.
• W2024001803 title "Covalent Modification of Cyclooxygenase-2 (COX-2) by 2-Acetoxyphenyl Alkyl Sulfides, a New Class of Selective COX-2 Inactivators" @default.
• W2024001803 cites W1485442945 @default.
• W2024001803 cites W1520750411 @default.
• W2024001803 cites W1536681507 @default.
• W2024001803 cites W1660326086 @default.
• W2024001803 cites W1976654542 @default.
• W2024001803 cites W1982273085 @default.
• W2024001803 cites W1987920649 @default.
• W2024001803 cites W1988514800 @default.
• W2024001803 cites W1991286536 @default.
• W2024001803 cites W1996055867 @default.
• W2024001803 cites W1997364548 @default.
• W2024001803 cites W1997761684 @default.
• W2024001803 cites W2002341330 @default.
• W2024001803 cites W2009132110 @default.
• W2024001803 cites W2014664456 @default.
• W2024001803 cites W2023200971 @default.
• W2024001803 cites W2024608254 @default.
• W2024001803 cites W2026608824 @default.
• W2024001803 cites W2030850720 @default.
• W2024001803 cites W2033498682 @default.
• W2024001803 cites W2034679499 @default.
• W2024001803 cites W2036866147 @default.
• W2024001803 cites W2039358393 @default.
• W2024001803 cites W2059750485 @default.
• W2024001803 cites W2063144963 @default.
• W2024001803 cites W2065088016 @default.
• W2024001803 cites W2115350007 @default.
• W2024001803 cites W2122355853 @default.
• W2024001803 cites W2325782876 @default.
• W2024001803 cites W2950555051 @default.
• W2024001803 cites W4238290414 @default.
• W2024001803 doi "https://doi.org/10.1021/jm980303s" @default.
• W2024001803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9822550" @default.
• W2024001803 hasPublicationYear "1998" @default.
• W2024001803 type Work @default.
• W2024001803 sameAs 2024001803 @default.
• W2024001803 citedByCount "109" @default.
• W2024001803 countsByYear W20240018032012 @default.
• W2024001803 countsByYear W20240018032013 @default.
• W2024001803 countsByYear W20240018032014 @default.
• W2024001803 countsByYear W20240018032015 @default.
• W2024001803 countsByYear W20240018032016 @default.
• W2024001803 countsByYear W20240018032017 @default.
• W2024001803 countsByYear W20240018032018 @default.
• W2024001803 countsByYear W20240018032019 @default.
• W2024001803 countsByYear W20240018032020 @default.
• W2024001803 countsByYear W20240018032021 @default.
• W2024001803 countsByYear W20240018032022 @default.
• W2024001803 countsByYear W20240018032023 @default.
• W2024001803 crossrefType "journal-article" @default.
• W2024001803 hasAuthorship W2024001803A5010503382 @default.
• W2024001803 hasAuthorship W2024001803A5017995984 @default.
• W2024001803 hasAuthorship W2024001803A5035452503 @default.
• W2024001803 hasAuthorship W2024001803A5039874956 @default.
• W2024001803 hasAuthorship W2024001803A5057630285 @default.
• W2024001803 hasConcept C104317684 @default.
• W2024001803 hasConcept C119157956 @default.
• W2024001803 hasConcept C178790620 @default.
• W2024001803 hasConcept C181199279 @default.
• W2024001803 hasConcept C185592680 @default.
• W2024001803 hasConcept C193042331 @default.
• W2024001803 hasConcept C202751555 @default.
• W2024001803 hasConcept C2778806918 @default.
• W2024001803 hasConcept C2779281246 @default.
• W2024001803 hasConcept C2779689624 @default.
• W2024001803 hasConcept C2780263894 @default.
• W2024001803 hasConcept C55493867 @default.
• W2024001803 hasConcept C56173144 @default.
• W2024001803 hasConcept C57992300 @default.
• W2024001803 hasConcept C71240020 @default.
• W2024001803 hasConceptScore W2024001803C104317684 @default.
• W2024001803 hasConceptScore W2024001803C119157956 @default.
• W2024001803 hasConceptScore W2024001803C178790620 @default.
• W2024001803 hasConceptScore W2024001803C181199279 @default.
• W2024001803 hasConceptScore W2024001803C185592680 @default.
• W2024001803 hasConceptScore W2024001803C193042331 @default.
• W2024001803 hasConceptScore W2024001803C202751555 @default.
• W2024001803 hasConceptScore W2024001803C2778806918 @default.
• W2024001803 hasConceptScore W2024001803C2779281246 @default.
• W2024001803 hasConceptScore W2024001803C2779689624 @default.
• W2024001803 hasConceptScore W2024001803C2780263894 @default.
• W2024001803 hasConceptScore W2024001803C55493867 @default.
• W2024001803 hasConceptScore W2024001803C56173144 @default.
• W2024001803 hasConceptScore W2024001803C57992300 @default.
• W2024001803 hasConceptScore W2024001803C71240020 @default.
• W2024001803 hasIssue "24" @default.
• W2024001803 hasLocation W20240018031 @default.
• W2024001803 hasLocation W20240018032 @default.

• next